CD20 mimicry by a mAb rituximab-specific linear peptide: a potential tool for active immunotherapy of autoimmune diseases.

摘要: An attractive, whether alternative or complementary, approach to passive immunotherapy (IT) with the anti-CD20 mAb rituximab for treatment of autoimmune diseases is stimulate host produce an immune response by using peptides that mimic CD20 (mimotopes). The only mimotope reported target antigen a 43-mer polypeptide corresponding exposed domain molecule (from amino acid 142 184). Owing its length, however, it failed efficiently induce CD20-specific response. A search has now been made smaller biopanning phage-display peptide library rituximab. total 10 positive phage clones expressing six distinct sequences were isolated. Their alignment produced motif did not match any portion extracellular loop, whereas bearing 12-mer linear Rp10-L specifically reacted and inhibited binding CD20. Furthermore, in BALB/c mice Rp10-L-induced antibodies CD20(+) B lymphoid cell line Raji but C20(-) T CEM. This currently being investigated determine effectiveness CD20-based active IT diseases.